2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.40 Savolitinib Plus Osimertinib for Previously Untreated NSCLC Patients with EGFR Mutations and Met-Amplification: A Case Series

EP.12A.40 Savolitinib Plus Osimertinib for Previously Untreated NSCLC Patients with EGFR Mutations and Met-Amplification: A Case Series

Back to course

Pdf Summary

The case series presented evaluates the use of savolitinib combined with osimertinib as a first-line treatment for non-small cell lung cancer (NSCLC) patients who have both EGFR mutations and MET amplification. NSCLC patients with these characteristics pose a unique challenge, as primary MET amplification is rare and may induce resistance to standard EGFR tyrosine kinase inhibitors (TKIs).<br /><br />In this study, three patients aged between 55 and 67 years, all with adenocarcinoma histology and without a smoking history, were treated with this combination therapy. The results revealed promising efficacy, as all patients showed a partial response to the treatment, with the response times ranging from 19 to 45 days. The progression-free survival spanned from 16 to 38 months, with treatments still ongoing as of July 2024. One reported adverse event was Grade 1 nausea, indicating an acceptable safety profile.<br /><br />The study emphasizes that savolitinib plus osimertinib displays rapid and durable antitumor effects in previously untreated advanced NSCLC patients with these genetic mutations, regardless of the specific EGFR mutation status. Furthermore, it points to the need for further research to validate the preliminary findings in larger patient cohorts to establish the combination as a standard first-line treatment option.<br /><br />While the current results are promising, the small sample size of the study and the absence of a control group underscore the necessity for broader clinical trials to confirm efficacy and safety comprehensively. The findings contribute to the growing evidence supporting targeted combination therapies that could potentially overcome primary resistance mechanisms in specific NSCLC patient subgroups.

Asset Subtitle

Kui Xiao

Meta Tag

Speaker Kui Xiao

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

savolitinib

osimertinib

NSCLC

EGFR mutations

MET amplification

adenocarcinoma

tyrosine kinase inhibitors

partial response

progression-free survival

targeted therapy